De Novo device
OraQuick Ebola Rapid Antigen Test
OraSure Technologies, Inc. · Device To Detect Antigens Of Biothreat Microbial Agents In Human Clinical Specimens (QID, Class II) · First FDA decision Oct 10, 2019, newest Oct 10, 2019
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "OraQuick Ebola Rapid"
MAUDE reports
0
Brand "OraQuick Ebola Rapid", since 2015
PubMed studies
4
Mentioning "OraQuick Ebola Rapid"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OraQuick Ebola Rapid Antigen Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- OraQuick Ebola Rapid Antigen TestNew device typeBreakthroughDe Novo
DEN190025 · Decided Oct 10, 2019 · 150 days after receipt
Device type: Device To Detect Antigens Of Biothreat Microbial Agents In Human Clinical Specimens (QID) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "OraQuick Ebola Rapid", any status and sponsor, newest update first.
No registered device study names "OraQuick Ebola Rapid".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OraQuick Ebola Rapid", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QID
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "OraQuick Ebola Rapid"[tiab]. The summary above synthesizes these.
- Postmortem Surveillance for Ebola Virus Using OraQuick Ebola Rapid Diagnostic Tests, Eastern Democratic Republic of the Congo, 2019-2020.
Mukadi-Bamuleka D, Sanogo YO, Bulabula-Penge J, et al. · Emerg Infect Dis · 2022
- Field performance of three Ebola rapid diagnostic tests used during the 2018-20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study.
Mukadi-Bamuleka D, Bulabula-Penge J, De Weggheleire A, et al. · Lancet Infect Dis · 2022Multicenter Study, Observational Study
- Development and Clinical Evaluation of a Rapid Point of Care Test for Ebola Virus Infection in Humans.
Wang Z, Bennett RS, Roehler M, et al. · Viruses · 2023Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural
- Head-to-head comparison of diagnostic accuracy of four Ebola virus disease rapid diagnostic tests versus GeneXpert® in eastern Democratic Republic of the Congo outbreaks: a prospective observational study.
Mukadi-Bamuleka D, Bulabula-Penge J, Jacobs BKM, et al. · EBioMedicine · 2023Observational Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.